Main Menu

Fusion Pharmaceuticals Inc.


Rigrodsky Law, P.A. is investigating Fusion Pharmaceuticals Inc. (“Fusion”) regarding possible breaches of fiduciary duties and other violations of law related to Fusion’s agreement to be acquired by AstraZeneca. Under the terms of the agreement, Fusion shareholders will receive $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/25/2024

* Indicates a required field.

Back to Page